All In Biotech

Drug Trial Radar · NCT04847232

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,690 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,690

Actual

Start

Apr 30, 2021

Primary completion

Mar 7, 2024

Study completion Mar 7, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.

Conditions

  • Hyperkalemia

Interventions

  • Sodium Zirconium Cyclosilicate (SZC)Drug

    Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).

  • SZC PlaceboDrug

    Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of the Composite of Cardiac Event OutcomesTime frame: From Randomization (Visit 4) up to week 129 (Randomized Study Intervention Phase)

Locations

340 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mesa, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Glendale, California

  • Research Site

    Granada Hills, California

  • Research Site

    Lynwood, California

  • Research Site

    San Diego, California

  • Research Site

    Vacaville, California

  • Research Site

    Victorville, California

  • Research Site

    Denver, Colorado

  • Research Site

    Bloomfield, Connecticut

  • Research Site

    Middlebury, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Columbus, Georgia

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Statesboro, Georgia

  • Research Site

    Nampa, Idaho

  • Research Site

    Iowa City, Iowa

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Detroit, Michigan

  • Research Site

    Kalamazoo, Michigan

  • Research Site

    Roseville, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Brookhaven, Mississippi

  • Research Site

    Columbus, Mississippi

  • Research Site

    Tupelo, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Jersey City, New Jersey

  • Research Site

    Manhasset, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    New Bern, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Bethlehem, Pennsylvania

Showing 40 of 340 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.